

Washington University School of Medicine

Digital Commons@Becker

---

Open Access Publications

---

2-1-2021

## Capsule carbohydrate structure determines virulence in *Acinetobacter baumannii*

Yuli Talyansky

Travis B. Nielsen

Jun Yan

Ulrike Carlino-Macdonald

Gisela Di Venanzio

*See next page for additional authors*

Follow this and additional works at: [https://digitalcommons.wustl.edu/open\\_access\\_pubs](https://digitalcommons.wustl.edu/open_access_pubs)

---

---

**Authors**

Yuli Talyansky, Travis B. Nielsen, Jun Yan, Ulrike Carlino-Macdonald, Gisela Di Venanzio, Somnath Chakravorty, Amber Ulhaq, Mario F. Feldman, Thomas A. Russo, Evgeny Vinogradov, Brian Luna, Meredith S. Wright, Mark D. Adams, and Brad Spellberg

---

## RESEARCH ARTICLE

Capsule carbohydrate structure determines virulence in *Acinetobacter baumannii*

Yuli Talyansky<sup>1</sup>, Travis B. Nielsen<sup>1,2,3</sup>, Jun Yan<sup>1</sup>, Ulrike Carlino-Macdonald<sup>4</sup>, Gisela Di Venanzio<sup>5</sup>, Somnath Chakravorty<sup>4</sup>, Amber Ulhaq<sup>1</sup>, Mario F. Feldman<sup>5</sup>, Thomas A. Russo<sup>4</sup>, Evgeny Vinogradov<sup>6</sup>, Brian Luna<sup>1</sup>, Meredith S. Wright<sup>7</sup>, Mark D. Adams<sup>8</sup>, Brad Spellberg<sup>9\*</sup>

**1** Department of Molecular Microbiology & Immunology, University of Southern California, Los Angeles, California, United States of America, **2** Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America, **3** Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois, United States of America, **4** Division of Infectious Diseases, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Veterans Administration, Buffalo, New York, United States of America, **5** Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, United States of America, **6** National Research Council Canada, Human Health Therapeutics Centre, Ottawa, Canada, **7** Rady Children's Institute for Genomic Medicine, San Diego, California, United States of America, **8** The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, United States of America, **9** LAC+USC Medical Center, Los Angeles, California, United States of America

\* [bspellberg@dhs.lacounty.gov](mailto:bspellberg@dhs.lacounty.gov)



## OPEN ACCESS

**Citation:** Talyansky Y, Nielsen TB, Yan J, Carlino-Macdonald U, Di Venanzio G, Chakravorty S, et al. (2021) Capsule carbohydrate structure determines virulence in *Acinetobacter baumannii*. PLoS Pathog 17(2): e1009291. <https://doi.org/10.1371/journal.ppat.1009291>

**Editor:** David S. Weiss, Emory University School of Medicine, UNITED STATES

**Received:** May 27, 2020

**Accepted:** January 7, 2021

**Published:** February 2, 2021

**Copyright:** © 2021 Talyansky et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the manuscript and its [Supporting Information](#) files.

**Funding:** This work was supported by National Institutes of Health/National Institute of Allergy and Infectious Diseases grants: NIH/NIAID R01 AI130060; R42 AI106375; R01 AI117211; R21 AI132923-01 (BS), NIH/NIAID R01 AI139052 (BL), NIH/NIAID R01 AI125363 (MFF), NIH 1R56AI129986-01 (TAR), NIH/NIAID AI134726-01 (BS and TAR) and the Department of Veterans

## Abstract

*Acinetobacter baumannii* is a highly antibiotic-resistant bacterial pathogen for which novel therapeutic approaches are needed. Unfortunately, the drivers of virulence in *A. baumannii* remain uncertain. By comparing genomes among a panel of *A. baumannii* strains we identified a specific gene variation in the capsule locus that correlated with altered virulence. While less virulent strains possessed the intact gene *gtr6*, a hypervirulent clinical isolate contained a spontaneous transposon insertion in the same gene, resulting in the loss of a branchpoint in capsular carbohydrate structure. By constructing isogenic *gtr6* mutants, we confirmed that *gtr6*-disrupted strains were protected from phagocytosis *in vitro* and displayed higher bacterial burden and lethality *in vivo*. *Gtr6*+ strains were phagocytized more readily and caused lower bacterial burden and no clinical illness *in vivo*. We found that the CR3 receptor mediated phagocytosis of *gtr6*+, but not *gtr6*-, strains in a complement-dependent manner. Furthermore, hypovirulent *gtr6*+ strains demonstrated increased virulence *in vivo* when CR3 function was abrogated. In summary, loss-of-function in a single capsule assembly gene dramatically altered virulence by inhibiting complement deposition and recognition by phagocytes across multiple *A. baumannii* strains. Thus, capsular structure can determine virulence among *A. baumannii* strains by altering bacterial interactions with host complement-mediated opsonophagocytosis.

Affairs VA Merit Review 1 I01 BX004677-01A1 (TAR). <https://www.niaid.nih.gov> and <https://www.va.gov/> The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** The authors have declared that no competing interests exist.

## Author summary

*Acinetobacter baumannii* is one of the most antibiotic-resistant pathogens in clinical medicine and is responsible for a significant number of deaths worldwide. We found that a highly virulent strain contained a mobile piece of DNA in one of its capsule assembly genes which rendered the gene inactive and thus removed a single sugar from the bacterium's complex outer carbohydrate capsule. When we inactivated the same gene in a non-virulent related strain, it became virulent, and when we repaired the non-functional gene the virulent strain became non-virulent. We then determined that this single sugar was critical for innate immune cells to recognize and phagocytose bacteria, and that the cells depended on the deposition of host complement proteins on the capsule to recognize the strains with this extra sugar. This finding provides new insight into *A. baumannii* pathogenesis and may inform the development of future therapies against this insidious pathogen.

## Introduction

For the past two decades, *Acinetobacter baumannii* clinical infections have been on the rise due to its facile antimicrobial resistance repertoire, catapulting the organism into the public health spotlight. Indeed, *A. baumannii* is now the top priority listed on the World Health Organization list of pathogens requiring new therapeutic strategies [1]. Causing approximately 45,000 infections in the US annually (1 million worldwide), it has an abnormally high mortality rate relative to other Gram-negative species [2]. Typically acquired nosocomially, *A. baumannii* resists desiccation, persists on surfaces, and is primarily seen in the critical care environment where many patients experience prolonged contact with invasive medical devices [3]. *A. baumannii* isolates exhibit resistance to multiple classes of antimicrobials, leaving certain strains treatable by few antimicrobial therapies and others altogether untreatable [4–6]. Together, these factors have made *A. baumannii* an intractable public health issue refractory to traditional infectious disease therapies and requiring further research into its interaction with the host immune system.

Previous work has uncovered the importance of innate immune effectors in responding to bloodstream and pulmonary infections, specifically of macrophages, neutrophils, and complement. An antibody raised against *A. baumannii* exopolysaccharide capsule mediated complete protection against a hypervirulent strain in murine models of bacteremia and aspiration pneumonia, with clearance occurring primarily through Fc-receptor mediated phagocytosis by macrophages and neutrophils [7]. In untreated mice, mortality primarily occurs via TLR-4 mediated toxicity and sepsis through the release of endogenous lipopolysaccharide (LPS), directly dependent upon bacterial density in the blood or lung [8]. A clear delineation of virulence has been established by strain type, with more than 99.9% of certain less-virulent strains being cleared by 3- to 4-log CFU/ml in blood in the first two hours, while more virulent strains persisted or even expanded in density in the presence of fully functional innate-immune system effectors. Triple depletion of macrophages, neutrophils, and complement induced the conversion of a hypovirulent, rapidly-cleared strain (ATCC 17978) into a hypervirulent strain capable of *in vivo* lethality similar to a hypervirulent clinical isolate (HUMC1) [7]. Thus, escape from innate immune effectors is a key driver of *A. baumannii* virulence.

Capsule is a potential driver of innate immune effector evasion. For example, genetic lesions in capsule assembly genes resulting in an acapsular phenotype typically result in absence of strain virulence *in vivo* [9,10]. Furthermore, sub-inhibitory concentrations of

chloramphenicol increase capsule thickness in *A. baumannii*, and increase both virulence and resistance to innate immune killing [11]. Nevertheless, both virulent and avirulent strains can have a functioning capsule [2], suggesting that variations in capsule structures, rather than presence or absence of capsule alone, may drive strain virulence. Here we present a mechanistic link between capsule structure and *A. baumannii* virulence using a strain collection of clinical isolates with well-defined capsule loci.

## Results

### Capsule genetic locus and carbohydrate structure

We previously defined the *in vivo* virulence of several *A. baumannii* clinical isolates [7,8,12]. After sequencing these strains we identified several with defined and relatively conserved [13] capsule loci genetic elements and highly variable virulence [2] through analysis with the Basic Local Alignment Search Tool (BLAST) (Table 1). *A. baumannii* HUMC1, a hypervirulent clinical blood and lung isolate, contains a KL22-type capsule locus type per the Kenyon classification [13]. ATCC 17978, a lab-adapted avirulent reference strain originally isolated from cerebrospinal fluid more than 50 years ago, is a KL3-type strain. Only two differences were found in the capsule loci of these strains, which exhibit vastly different *in vivo* virulence [14]. First was the presence of an extra gene (*pgt1*) near the end of the capsule locus in the KL22 type strain (HUMC1), and not in the KL3 strain (ATCC 17978). Second was a transposon insertion near the end of the *gtr6* coding region resulting in a truncated mRNA sequence in the hypervirulent strain, HUMC1 (Fig 1A). BLAST analysis of the *gtr6* insertion revealed it to be already classified as ISAb13, belonging to Insertion Family 5 and Group 903, and present in over 50 strains of *A. baumannii*, some of which were confirmed to be clinical isolates.


When these two differences between HUMC1 and ATCC 17978 capsule loci were evaluated in other KL22- and KL3-type strains, we found that strains with intact *gtr6* genes were readily phagocytosed [12] (Table 1). In contrast, *pgt1* was present in strains that had both low uptake (HUMC1) and high uptake (15827 and NIH1), and could therefore not be principally responsible for phagocytic phenotype.

Translated BLAST analysis predicted the *gtr6* gene to most likely be a glycosyltransferase and *pgt1* to be a phosphoglycerol transferase or sulfatase. After extraction and purification of HUMC1, ATCC 17978, and 15827 capsular polysaccharides, proton nuclear magnetic resonance (<sup>1</sup>H-NMR) and two-dimensional NMR spectra were obtained for each strain to determine their structural configuration. All strains shared a core structure composed of a repeating subunit of  $\alpha$ -D-galactose,  $\beta$ -D-glucose, and N-acetyl- $\beta$ -D-galactosamine (Residues B, C, and D in Fig 1B). They also contained a single N-acetyl- $\beta$ -D-glucosamine side chain

**Table 1. Strains by Locus Classification, Genotype, and Phagocytosis Phenotype.** All strains used in this study are described according to Kenyon classification capsule assembly locus type, genotype by *gtr6* and *pgt1*, and relative phagocytic potential.: = chromosomal gene insertion, / = plasmid insertion, \* = generated mutant.

Strain	Locus Type	<i>gtr6</i>	<i>pgt1</i>	Phagocytosis
HUMC1	KL22	-	+	Low
NIH1	KL22	+	+	High
15827	KL22	+	+	High
ATCC 17978	KL3	+	-	High
ATCC 17978 $\Delta$ <i>gtr6</i> *	KL3	-	-	Low
ATCC 17978 $\Delta$ <i>gtr6</i> /pSC1a*	KL3	+	-	High
NIH1 $\Delta$ <i>gtr6</i> *	KL22	-	-	Low
HUMC1:: <i>gtr6</i> *	KL22	+	+	High

<https://doi.org/10.1371/journal.ppat.1009291.t001>



**Fig 1. Capsular gene loci for *A. baumannii* KL3 and KL22 and capsular carbohydrate composition and linkage of KL22, and KL3 capsule locus strains.** (A) Whole-genome sequencing of HUMC1 (a hypervirulent strain), 15827 (a hypovirulent strain) and ATCC 17978 (an avirulent strain) revealed distinct capsule loci organized into KL22 (HUMC1 and 15827) and KL3 (ATCC 17978) groups. KL22 differs from KL3 in that it contains an extra acetyltransferase gene *pgt1*, while HUMC1 (KL22) contains a transposon insertion sequence disruption in the coding region of the glycotransferase *gtr6* (downward black arrow). We then disrupted the *gtr6* gene in ATCC 17978 through the insertion of an antibiotic resistance cassette in its coding (upward black arrow), and then by replacing the entire gene with a defective copy from HUMC1. (B) (Top) Structural analysis of hypervirulent HUMC1 and the ATCC 17978 Δ*gtr6* mutant (KL3) revealed differential levels of acetylation at the A4 position marked in grey highlight (90% for *pgt1*<sup>+</sup> HUMC1 and 50% for *pgt1*<sup>-</sup> ATCC 17978 Δ*gtr6*). The two strains are isogenic at the capsule locus save for *pgt1*. (Bottom) Structural analysis of avirulent ATCC 17978 and hypovirulent 15827 (KL22) revealed the same *pgt1*-mediated difference in acetylation as well as an additional GlcNAc branch at position B (grey rectangle). Both KL22 and KL3 loci have a functioning *gtr6* gene.


<https://doi.org/10.1371/journal.ppat.1009291.g001>

branching off of Residue B that was differentially acetylated (Residue A), with 50% overall acetylation in *pgt1*<sup>-</sup> strains (ATCC 17978) versus 90% acetylation in *pgt1*<sup>+</sup> strains (HUMC1 and 15827). Strains with intact *gtr6* (ATCC 17978 and 15827) had an additional single sugar residue consisting of an N-acetyl-β-D-glucosamine (Residue E) branching off of Residue B. This residue was absent in the HUMC1 strain, which has a spontaneously disrupted *gtr6* gene, suggesting that the disruption or absence of *gtr6* led to loss of Residue E.

### Construction and comparison of isogenic strain pairs

To better understand the role of *gtr6* in virulence, we created a series of isogenic strain pairs and compared them for virulence *in vitro* and *in vivo*. Specifically, we disrupted *gtr6* in ATCC 17978 and NIH1; created a revertant strain of the *gtr6*-disrupted ATCC 17978 mutant by





**Fig 2. Macrophage phagocytosis of ATCC 17978  $\Delta gtr6$ , NIH1  $\Delta gtr6$ , and HUMC1::gtr6, gentamicin protection assay, and representative micrographs.** (2A) RAW 264.7 cells were co-incubated with NIH1 (left) and ATCC 17978 (right) isogenic wild-type strains and  $\Delta gtr6$  mutants. (2B) RAW 264.7 cells were co-incubated with ATCC 17978, the HUMC1::gtr6 mutant strain with repaired gtr6, or wild-type HUMC1. (2C) RAW 264.7 cells were co-incubated with ATCC 17978 wild type,  $\Delta gtr6$ ,  $\Delta gtr6/pSC1a$  (the knockout mutant with a plasmid-borne functional copy) in the presence of complement-active serum, and  $\Delta gtr6/pSC1a$  in the presence of heat-inactivated serum. \*  $p < 0.001$ . (2D) Gentamicin protection assay with RAW 264.7 cells and wild-type ATCC 17978 (black bars) or ATCC 17978  $\Delta gtr6$  (white bars). Cytochalasin D was added as an inhibitor of phagocytosis. Total bacteria plated for CFUs and expressed as a proportion of initial bacterial inoculum. \* = significant vs. bacteria-only group, † = significant vs. bacteria + RAW 264.7 cell group. \*, †  $p < 0.01$  (2E) RAW 264.7 cells were incubated with ATCC 17978, HUMC1, ATCC 17978  $\Delta gtr6$ , and HUMC1::gtr6. Stained with Wright-Giemsa stain, total magnification is 1000x. Results are from two repeat experiments with duplicate samples in each. White arrows denote adherent or internalized bacteria.

<https://doi.org/10.1371/journal.ppat.1009291.g002>


transforming it with a functioning *gtr6*-containing plasmid; and repaired the spontaneous transposon disruption of *gtr6* in HUMC1 with a functional copy from ATCC 17978. Capsule carbohydrate analysis of ATCC 17978  $\Delta gtr6$  revealed the loss of the N-acetyl- $\beta$ -D-glucosamine residue seen in the wild type strain (residue E above) as well as the retention of 50% acetylation of residue A consistent with the absence of a *pgt1* gene in the mutant strain.

As previously published, HUMC1 is intrinsically resistant to phagocytosis by neutrophils and macrophages, resulting in increased virulence in intravenous and intratracheal mouse infection models [14]. As for ATCC 17978 and NIH1, newly constructed strains with disrupted *gtr6* exhibited similar degrees of marked reduction in phagocytic uptake compared to their isogenic strains with intact *gtr6* (Fig 2A). In contrast, HUMC1 with repaired *gtr6* exhibited markedly increased uptake similar to all other strains with intact *gtr6* (Fig 2B). Representative micrograph images of RAW 264.7 bacterial uptake are reproduced in Fig 2E.

Additionally, rescue of the ATCC 17978  $\Delta gtr6$  mutant with a *gtr6*-containing plasmid restored phagocytic uptake (Fig 2C). RNA sequencing analysis of wild-type HUMC1 and HUMC1::*gtr6* revealed no differential gene expression outside of the capsule locus (S1A Fig).

Bacterial internalization following adhesion was additionally confirmed through gentamicin protection assays using ATCC 17978 WT and ATCC 17978  $\Delta gtr6$  (Fig 2D). Specifically, gentamicin completely sterilized ATCC 17978 WT and  $\Delta gtr6$ , but was prevented from doing so when macrophages were co-cultured with the *gtr6*<sup>+</sup> strain but not the  $\Delta gtr6$  mutant, indicating macrophage uptake of the *gtr6*<sup>+</sup> strain (as gentamicin is active extracellularly but cannot reach bacteria inside macrophages). Furthermore, cytochalasin D, which abrogates phagocytosis, prevented macrophages from reducing *gtr6*<sup>+</sup> bacterial burden in culture and also prevented macrophages from protecting *gtr6*<sup>+</sup> bacteria from gentamicin-mediated sterilization.

When tested *in vivo* using a bacteremia mouse model, strains with disrupted *gtr6* resulted in markedly higher blood bacterial burden at 1-hour post-infection than those with intact *gtr6* (Fig 3A). We next compared the virulence of isogenic strain pairs *in vivo* and found that all



**Fig 3. Bacterial blood burden and *in vivo* lethality by *gtr6* genotype.** (3A) Bacterial burden in the blood at 1-hour post-infection with  $1.0 \times 10^8$  CFUs of ATCC 17978 WT and  $\Delta gtr6$  (left) and NIH1 WT and  $\Delta gtr6$  (right). \* $p < 0.001$  (3B) C3HeB/Fe mice were infected intravenously with  $2.4 \times 10^8$  CFUs of ATCC 17978 (black squares),  $8.3 \times 10^7$  CFUs of ATCC 17978  $\Delta gtr6$  (white squares),  $1.0 \times 10^8$  CFUs of NIH1 (black circles) and NIH1  $\Delta gtr6$  (white circles),  $2.9 \times 10^7$  CFU of HUMC1 (black triangles), and  $2.0 \times 10^8$  CFUs of HUMC1::*gtr6* (white triangles). \* $p < 0.05$ , \*\* $p < 0.01$ . Wide bars denote median, error bars denote IQR. Experiments repeated once,  $n = 5$  per group for *in vivo*.

<https://doi.org/10.1371/journal.ppat.1009291.g003>




strains with disrupted *gtr6* (ATCC 17978  $\Delta gtr6$ , NIH1  $\Delta gtr6$ , and HUMC1) were hypervirulent while all strains with intact *gtr6* (ATCC 17978, NIH1) were non-lethal (Fig 3B). Most notably, the *gtr6*-repaired mutant (HUMC1::*gtr6*) lost its virulence and was non-lethal at a 10-fold higher dose than the LD<sub>100</sub> of wild type HUMC1 (Fig 3B).

### Mechanism of altered capsule structure on phagocytosis

Having established that *gtr6* disruption abrogates *A. baumannii* adhesion and subsequent phagocytosis *in vitro* and diminishes clearance and survivability *in vivo*, we next sought to determine how the capsule structure change mediated this effect.

We first verified that *gtr6* did not affect capsule abundance by quantitatively measuring total carbohydrate content in capsule extracts (Fig 4A). We subsequently sought to determine whether the *gtr6*-disrupted capsule actively inhibited phagocytosis or, conversely, *gtr6*-intact capsule promoted phagocytosis. We conducted mixed phagocytosis assays in which soluble



**Fig 4. Quantification of capsule content, pre-incubation of phagocytes with purified bacterial capsule, and pre-incubation of phagocytes with soluble carbohydrates.** (4A)  $2.0 \times 10^8$  CFU of ATCC 1778 and HUMC1 had total capsule carbohydrate capsule extracted in parallel and total carbohydrate content measured via phenol-sulfuric acid colorimetry. (4B) Incubation of macrophages and bacteria with purified capsule from *gtr6*<sup>+</sup> (ATCC 17978, 15827) and *gtr6*<sup>-</sup> (HUMC1, ATCC 17978  $\Delta gtr6$ ) strains. Extract-free uptake was used as a control. \* $p < 0.0001$  (4C) RAW 264.7 cells were pre-incubated with soluble mannan (0.5mg/mL), laminarin (0.5mg/mL), and dextran sulfate (0.1mg/mL) or an untreated control prior to co-incubation with ATCC 17978. \* $p < 0.0001$ . Two biological replicates for *in vitro*. Wide bars denote median, error bars denote IQR.

<https://doi.org/10.1371/journal.ppat.1009291.g004>

capsule was extracted from strains and added to macrophage cultures in the presence of viable bacteria. We found that capsule extracted from *gtr6*-intact strains inhibited uptake of ATCC 17978 whereas capsule from *gtr6*-disrupted strains did not alter uptake of bacteria (Fig 4B). Thus, rather than actively inhibiting uptake, *gtr6*-disrupted strains produce a capsule structure that is unrecognizable by phagocytic receptors while not altering capsule abundance.

We next sought to identify which receptors were driving adhesion and phagocytosis of *gtr6*-intact strains. By pre-incubating macrophages with various carbohydrate targets of phagocytic receptors, we found that laminarin—but not mannan or dextran sulfate—inhibited the uptake of the normally highly phagocytosed strain ATCC 17978 (Fig 4C).


Given that laminarin blocked phagocytosis of ATCC 17978 we next sought to block the known phagocytic receptors of laminarin using neutralizing monoclonal antibodies. Laminarin, a branched 1,3- and 1,6-linked  $\beta$ -glucan fungal sugar, is known to bind a number of mammalian C-type lectins including Dectin-1 and Complement Receptor 3 (CR3) [15]. We next performed phagocytosis assays with macrophages, *gtr6*-intact ATCC 17978, and neutralizing antibodies to identify which receptor interacted with capsular carbohydrate from *gtr6*-intact strains: anti-CR3 antibodies considerably decreased phagocytic uptake, anti-Dectin-1 antibodies modestly but statistically significantly decreased phagocytic uptake, and no decrease in phagocytosis was seen with anti-Mannose Receptor (MR) consistent with unaltered uptake upon pre-incubation with soluble mannan (Fig 5A).

To verify the involvement of CR3 in recognition of ATCC 17978, we knocked down CR3 and Dectin-1 mRNA in RAW 264.7 cells by siRNA transfection followed by phagocytosis assays. Consistent with prior siRNA results in this cell line [16], siRNA knockdown of CR3 resulted in a 50–75% receptor knockdown efficiency via  $\Delta\Delta$ Ct RT-qPCR (S1B Fig). Mimicking the effect of neutralizing antibodies, macrophages transfected with anti-CR3 siRNA showed a significant decrease in uptake of ATCC 17978, with a non-significant decrease in Dectin-1 and no additive effects with a dual Dectin-1/CR3 knockdown (Fig 5B).

Phagocytosis assays using peritoneal macrophages from Dectin-1- and CR3-knockout (KO) mice via 72-hour elicitation with Brewer thioglycolate medium yielded similar results. Specifically, CR3 null macrophages mediated drastically less uptake than macrophages from wild type or Dectin-1 KO animals (Fig 5C). Shorter duration (24-hour) thioglycolate elicitation yielding peritoneal neutrophils showed genotypically similar results to macrophages (Fig 5D), and heat inactivation of complement by heating at 56°C for 30 minutes completely abrogated uptake in primary peritoneal neutrophils and RAW 264.7 macrophages (Fig 5D and 5E).

## The role of complement in mediating virulence

The dependence of phagocytes on CR3 and complement-active serum to uptake *gtr6*-intact strains suggested that complement deposition of iC3b is a primary driver of bacterial clearance. CR3 consists of both a complement-recognizing protein-binding domain and a carbohydrate-recognizing lectin domain [17], so we next sought to rule out any redundant effects between the two. To this end, we first antagonized the lectin-binding domain by pre-incubating macrophages with an inhibitory concentration [18] of soluble N-acetyl-D-glucosamine. Blockade of the CR3 lectin-binding domain in this manner did not alter uptake of bacteria in the presence of complement-active serum (Fig 6A). Serially diluting complement active serum demonstrated the dependence of macrophages on complement to uptake *gtr6*-intact ATCC 17978, with a significant loss of uptake occurring at ultra-low concentrations of complement of  $\leq 1\%$  (Fig 6B). Thus, even low amounts of complement were sufficient to drive CR3-mediated uptake of *A. baumannii*.




**Fig 5. Receptor blockade with siRNA knockdown, antibody neutralization of beta-glucan receptors prior to bacterial uptake, and phagocytosis of bacteria by peritoneal macrophages and neutrophils.** (5A) RAW 264.7 cells were pre-incubated with anti-Dectin-1, anti-CR3, anti-MR neutralizing monoclonal antibodies or an isotype control prior to co-incubation with ATCC 17978. \* $p < 0.0005$ , \*\* $p < 0.0001$  (5B) Knockdown of Dectin-1 and/or CR3 in RAW 264.7 cells followed by incubation with ATCC 17978. \* $p < 0.0001$  (5C) Primary peritoneally-elicited macrophages from C57BL/6 mice followed by phagocytosis assays with ATCC 17978. \* $p < 0.05$ , \*\* $p < 0.0001$  (5D) Phagocytosis assays of ATCC 17978 with peritoneal neutrophils from wild-type mice with

disruption of phagocytosis upon the addition of heat-inactivated serum (HI-S) or complement-active serum (CA-S). \* $p < 0.0001$  (5E) Phagocytosis assays with RAW 264.7 macrophages with *gtr6*<sup>+</sup> and capsule-free strains (ATCC 17978 WT, 15827, ATCC 17978  $\Delta$ *itrA*), and *gtr6*<sup>-</sup> strains (ATCC 17978  $\Delta$ *gtr6*, HUMC1), with complement active (CA-S) or heat-inactivated (HI-S) serum. \* $p < 0.0001$ . Experiments repeated once with two biological replicates. Wide bars denote median, error bars denote IQR.


<https://doi.org/10.1371/journal.ppat.1009291.g005>

To establish the ability of complement to rescue mice from *A. baumannii* infection, we compared the concentrations of lethal inocula across strains in a murine bacteremia model, with mice depleted of complement using cobra venom factor (CVF) [19]. We previously found that *A. baumannii* strain 15827 was nonlethal at an inoculum of  $2 \times 10^8$  CFU whereas HUMC1—which has an identical KL22 capsule locus except for the *gtr6* disruption—was 100% lethal at an inoculum 10-fold lower [12]. 15827 also became highly lethal in mice depleted of complement relative to fully functional controls (Fig 6C).



**Fig 6. Phagocytosis in the presence of a lectin domain inhibitor, phagocytosis by macrophages in serially diluted serum, and infection of complement-depleted mice.** (6A) Incubation of RAW 264.7 cells with ATCC 17978 in the presence of 100µg/mL GlcNAc (NAG), a CR3 lectin domain inhibitor. (6B) Serial two-fold dilutions of complement-active mouse serum in a RAW 264.7 cell phagocytosis assay with ATCC 17978. \* $p < 0.0001$  (6C) Male C57BL/6 mice aged 10 weeks were infected intravenously with  $2.0 \times 10^8$  CFUs of 15827, with or without administration of 15µg cobra venom factor (CVF) 48 h prior to infection. \* $p < 0.001$ . Experiments repeated once,  $n = 5$  per group for *in vivo* and two technical replicates for *in vitro*.

<https://doi.org/10.1371/journal.ppat.1009291.g006>



**Fig 7. Flow cytometry of strains incubated with serum and anti-C3b antibodies.** (7A) Flow cytometry of bacteria following incubation in 10% complement active serum followed by anti-C3b antibodies. Strains denoted by known virulence (brackets) as well as *gtr6* phenotype (upward arrows).  $p < 0.0001$ . (7B) Representative flow plot of initial forward and side scatter plot and sub-gating on single bacterial cells with FITC-A as the anti-C3b fluorophore. (7C) Representative histograms of anti-C3b fluorescent bacteria for HUMC1 (hypervirulent), 15827 (hypovirulent), ATCC 17978  $\Delta$ itrA (avirulent), and the isotype control. 20,000 events collected per condition for flow cytometry, gated for singlets via FSC/SSC, fluorescence gate set to exclude 99% of isotype control and copied across samples ran in parallel.

<https://doi.org/10.1371/journal.ppat.1009291.g007>

This led us to evaluate complement deposition on the bacterial surface. We first incubated bacterial strains with complement-active serum, followed by anti-C3b antibodies, and finally a fluorescent secondary antibody (Fig 7A, 7B and 7C). Flow cytometry revealed that C3b bound >40% of the *gtr6+* ATCC 17978, >95% of an acapsular mutant (ATCC 17978  $\Delta$ itrA), and was almost undetectable on the *gtr6-* strain (ATCC 17978  $\Delta$ gtr6). Complement binding to other hypovirulent strains (15827, AB0057, AB0071) was considerably lower (2–5% events bound by C3b), but still 5- to 10-fold higher than the panel of hypervirulent strains (HUMC4, HUMC5, HUMC1, LAC4) which were nearly imperceptible ( $\leq 1\%$  events bound by C3b). Thus, a small amount of complement deposition on the bacterial surface is sufficient to mediate phagocytic uptake *in vitro*. The role of C3 and C5 in phagocytosis were established via macrophage uptake assays of the strain panel in serum selectively depleted of C3 as well as C3/C5 in combination, as well as in entirely serum-free conditions. The presence of C3 was uniformly requisite for uptake (S1C Fig).



## Discussion

We have identified a single glycosyltransferase gene in the capsule locus that was capable of significantly modifying virulence in *A. baumannii*. A single  $\beta$ -D-Glc<sub>6</sub>NAc side chain alteration in the capsule dictated a hypovirulent versus hypervirulent phenotype in both wild-type and generated mutant strains. Strains lacking this key residue could not be readily phagocytized by innate immune effectors *in vitro*, nor be effectively cleared *in vivo*, and thus resulted in lethal infection. Conversely, strains possessing the *gtr6*-encoded capsular carbohydrate branch-point were readily adherent to immune cells, were phagocytosed, and were nonlethal *in vivo*.

Inserting both the transposon-disrupted HUMC1-derived *gtr6* gene as well as full disruption through replacement with an antibiotic cassette resulted in lack of phagocytosis and increased virulence, suggesting that the transposon insertion near the terminal coding region of *gtr6* in HUMC1 resulted in a complete functional knockout of the gene. Rescue of the ATCC 17978  $\Delta$ *gtr6* mutant with a *gtr6*-containing plasmid reverted the phagocytosis phenotype, confirming that *gtr6* function, rather than polar effects of gene editing, were responsible for the phagocytosis phenotype seen in the generated mutants. RNA sequencing of the *gtr6*-disrupted wild type HUMC1 as well as the *gtr6*+ HUMC1::*gtr6* rescue strain confirmed that the addition of *gtr6* did not change the expression levels of any genes outside of the capsule locus.

These results follow the molecular Koch's postulates modified for loss-of-function driving virulence [20], indicating that the bacterial capsule is a primary driver of virulence, as demonstrated across multiple clinical isolates and isogenic strain pairs. BLAST analysis confirmed that this insertion element has previously been characterized as ISAb13 and is present in a variety of *A. baumannii* clinical isolates, and other work confirms that frequent transposon-mediated disruption of genes contributes significantly to *A. baumannii* virulence in the form of outer molecule structural variation [21], metabolic function, and antimicrobial resistance [22,23].

One limitation of the data is that we cannot definitively distinguish which step in phagocytosis is altered by the *gtr6* gene. However, it is likely that capsular alteration affects adhesion, which is the first step in the phagocytosis cascade. The ATCC 17978  $\Delta$ *gtr6* mutant showed almost identical CFU levels in the bacteria-only and bacteria plus macrophage groups compared to a decrease in the bacteria plus macrophage group with wild type ATCC 17978, suggesting that the entire  $\Delta$ *gtr6* bacterial inoculum was present in the assay supernatant upon plating with no bacteria adherent to or sequestered in the RAW 264.7 cells. Likewise, the addition of cytochalasin D to gentamicin-containing wells did not alter gentamicin's effect on CFUs with the  $\Delta$ *gtr6* strain. This result suggests that gentamicin protection is mediated upstream of the cytochalasin target in the assay, which is actin-polymerization mediated phagocytosis, after adhesion had already occurred.

Multiple lines of evidence indicated CR3 as the primary receptor mediating uptake via complement deposited on the bacterial surface. As CR3 contains both a C-type lectin-binding domain that recognizes carbohydrates and a protein-binding domain that recognizes inactivated (but bound) complement factor 3b (iC3b) [24], both could have played a role in the recognition of *A. baumannii* [25]. However, heat-inactivating serum completely blocked bacterial uptake by both macrophages and neutrophils while incubation with a CR3 lectin domain inhibitor did not, indicating that *in vitro* phagocytosis by CR3 depended entirely on bound complement recognition by two innate immune effector cell types. Furthermore, serially diluting the serum present in macrophage uptake assays decreased bacterial uptake only at  $\leq 1\%$  serum. Thus, only a small amount of capsule-bound complement was necessary for recognition and phagocytosis. Selective depletion of C3 additionally prevented uptake as did entirely



serum-free conditions. Furthermore, capsule structure drove complement deposition. Specifically, an acapsular  $\Delta itrA$  mutant strain was virtually saturated via complement binding on its surface, hypovirulent strains with intact *gtr6* exhibited intermediate complement binding, and hypervirulent, *gtr6*-deficient strains (HUMC1 and ATCC 17978  $\Delta gtr6$ ) had very little C3b bound ( $\leq 1\%$  events), commensurate with their resistance to phagocytosis and clearance from the blood.

Interestingly, the *gtr6+*/*pgt1+* strain (15827) showed moderate levels of C3b binding ( $\sim 5\%$  events), less bound C3b than the *gtr6+*/*pgt1-* strain (ATCC 17978). These results suggested that *pgt1* may play a small role in protecting bacteria from complement opsonization, though insufficient for increasing strain virulence on its own. Previous work has described surface charge as being important in both promoting and inhibiting complement deposition on bacterial and artificial surfaces [26,27], and the higher acetylation in *pgt1+* strains may be minimally protective against complement deposition via this model by having an overall higher negative surface charge than *pgt1-* strains. The specific pathway by which *pgt1* differentially acetylates capsule remains unknown, as its predicted function as a phosphoglycerol transferase or sulfatase is not reflected in the KL22 structure. However, inconsistencies between its presence in the capsule locus and capsule structure have been described previously [28,29].

The *gna* gene, present in multiple strains including KL3 and KL22, is most likely responsible for the synthesis of GlcpNAcA from GlcpNAc while *dgaA*, *dgaB*, and *dgaC* (annotated as *mnmA-C* elsewhere) are responsible for the synthesis of GlcpNAc3NAcA [28], a modified side chain of which is present in both KL3 and KL22 but does not seem play a principal role in innate immune recognition given that both ATCC 17978 and HUMC1 contain this residue in their capsule structures (although its differential acetylation may play a minimal role as discussed above). Notably, the hypervirulent clinical isolate LAC-4, which showed almost no complement deposition in our binding assay, has had its capsule structure characterized as KL49 [29], is entirely free of branch points, and consists of repeating subunits of  $\alpha$ -FucNAc,  $\alpha$ -D-GlcpNAc, and 8eLeg5Ac7Ac [30]. While containing a number of insertion sequences that potentially contribute to virulence [31], the LAC-4 capsule locus is free of insertion elements unlike HUMC1.

In conclusion, virulence across multiple strains of *A. baumannii* is driven primarily by interactions between bacterial capsule and distinct host innate effectors. Specifically, complement plays an integral role in coordinating phagocytosis, with its degree of deposition varying based on capsular polysaccharide structure, as mediated by the functionality of a capsule assembly gene. Capsule changes that preclude complement deposition markedly decreased phagocytic uptake via the protein-binding domain of the CR3 receptor, preventing bacterial clearance and leading to host death. We did not identify other receptors on host cells that were functionally redundant with CR3. However, Dectin-1 may play a minor role in host uptake of bacteria consistent with previous studies examining the relative contributions of CR3 and Dectin-1 in the uptake of glucan-bearing particles [15,32,33].

Capsule is thus a major virulence factor for *A. baumannii*, but a variety of other factors have been implicated in virulence as well [2,34,35]. While the intravenous bloodstream infection model mimics the second most common clinical manifestation of *A. baumannii* (bacteremia) [2], it is not necessarily safe to extrapolate to other disease settings (e.g., pneumonia, wound infections, urinary tract infections), which may involve innate immune effectors that differ significantly from those present in the bloodstream. However, we have found that anti-capsular monoclonal antibody therapy is protective during pneumonia, suggesting capsule does play a major role in pathogenesis during lung infection [7].

In summary, these results indicate that anti-virulence strategies specifically targeting the *A. baumannii* capsule or promoting complement deposition on bacteria (for example by

antibody-based therapy) are promising means to prevent or treat serious infections caused by this deadly pathogen. Future work should determine how prevalent disruptions in *gtr6*, or other capsular alterations, are in clinical isolates of *A. baumannii*, and whether or not *gtr6*-positive strains are capable of innate immune evasion through an alternative mechanism.

## Materials and methods

### Ethics statement

All animal work was conducted following approval (Protocol # 20750) by the Institutional Animal Care and Use Committee at the University of Southern California, in compliance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Infected mice develop weight loss, ruffled fur, poor appetite, decreased ambulation, huddling behavior, and low body temperature. Mice were monitored at least twice daily for seven days. Mice that displayed huddling behavior and are poorly mobile were weighed once daily. Weight loss of greater than 15% pre-infection body weight triggered euthanasia via CO<sub>2</sub> chamber and secondary cervical dislocation. Soft bedding and other enrichment devices were provided as recommended by the veterinary staff. Nutritional supplements such as hydrogel packs were provided as needed.

### Genome BLAST analysis

Genomes were retrieved from NCBI with the following GenBank accession numbers: LQRQ00000000.1 (HUMC1), JMNX00000000.1 (15827), CP000521.1 (ATCC 17978), GCA\_000222225.2 (NIH1). Nucleotide BLAST comparison of their K capsule loci was performed by first aligning to *fkpA/lldP* and *ilvE/aspS* genes that flank the K locus [13], and differing genes were analyzed for structural homology to known proteins using translated BLAST at NCBI. The *gtr6* transposon insertion in HUMC1 (NCBI Reference Sequence NZ\_LQRQ01000007.1, transposon gene ID: AWC45\_RS01000) was entered into PATRIC for BLAST analysis and identified as ISAb13, belonging to Insertion Family 5 and Group 903.

### Knockout mutant generation

ATCC 17978  $\Delta gtr6$  and NIH1  $\Delta gtr6$ , isogenic derivatives of ATCC 17978 and NIH1 respectively, were generated by allelic exchange as described previously [36,37] with the following strain-specific selection marker and electroporation condition modifications. Electrocompetent cells were grown to OD<sub>600</sub> 0.4 in lysogeny broth (LB) containing 0.12 mM Bi(NO<sub>3</sub>)<sub>3</sub> and 2.5 mM sodium salicylate at pH 7 to decrease capsule production [38] followed by three washes with ice-cold 10% glycerol; cells were resuspended in sterile water to 500-fold pre-wash concentration. Electroporation was performed at 1.8 kV, 200  $\Omega$ , and 25  $\mu$ F in a 2-mm cuvette. As a first step, to facilitate allelic exchange, the recombinase-containing plasmid pAT02 was introduced into ATCC 17978 and NIH1 via electroporation and selection with 200  $\mu$ g/mL and 500  $\mu$ g/mL of carbenicillin respectively. For the subsequent generation of electrocompetent cells containing pAT02, 2 mM IPTG and the appropriate concentration of carbenicillin were added after an initial 45 min of growth. For the construction of ATCC 17978  $\Delta gtr6$  and NIH1  $\Delta gtr6$ , a PCR-generated fragment that contained a kanamycin resistance gene flanked by the first and last 126 bp of *gtr6* was amplified and gel-purified. This fragment (7.8  $\mu$ g) was electroporated into ATCC 17978/pAT02 or NIH1/pAT02 and recombinants were selected on LB plates containing 40  $\mu$ g/mL kanamycin. Successful gene disruption was confirmed by sequencing of PCR-generated amplicons using primers outside of the gene in question. A derivative

cured of pAT02 was used for subsequent studies. Strains were maintained at  $-80^{\circ}\text{C}$  in 50% glycerol-50% LB.

## HUMC1 mutant generation

**Strains, plasmids and growth conditions.** *Acinetobacter baumannii* strain HUMC1 was maintained in LB. Plasmids were maintained in *Escherichia coli* JM101 with requisite antibiotics at concentrations as follows, unless otherwise specified: hygromycin 100  $\mu\text{g}/\text{mL}$ ; chloramphenicol 20  $\mu\text{g}/\text{mL}$ ; carbenicillin 100  $\mu\text{g}/\text{mL}$ ; tetracycline 25  $\mu\text{g}/\text{mL}$ . Plasmids used for the study are listed in [S1 Text](#). *A. baumannii* HUMC1 being an XDR strain, was found to be resistant to ampicillin, however it was sensitive to tetracycline at high concentration (60  $\mu\text{g}/\text{mL}$ ).

**Construction of pAT03a.** *E. coli* JM101 was first transformed with pSIM5 encoding the  $\lambda$ -Red recombination system [37,39] and JM101/pSIM5 was further transformed with pAT03 (amp<sup>R</sup>). pAT03a possesses a gene for a site-specific recombinase (flippase) that was used downstream to excise the hygromycin antibiotic resistance gene cassette ([S2 Text](#)) from the recombinant clone of *A. baumannii* HUMC1::gtr6-hygromycin. The plasmid pAT03a ([S2A Fig](#)) was derived from pAT03, by exchanging the ampicillin resistance gene cassette with a tetracycline resistance gene cassette as follows. The tetracycline resistance gene cassette was amplified from the plasmid pBS-Tet<sup>r</sup> ([S1 Text](#)) using Q5 High-Fidelity Master Mix (NEB) using primer sets TetF and TetR ([S3 Text](#)). The 200- $\mu\text{L}$  PCR reaction contained 80 ng DNA pBS-Tet<sup>r</sup> template and primers at 0.5  $\mu\text{M}$ . The mix was divided equally into four tubes and the amplification was done as follows: initial denaturation at  $98^{\circ}\text{C}$  for 3 min followed by 35 cycles of  $96^{\circ}\text{C}$  for 10 s,  $62^{\circ}\text{C}$  for 30 s,  $72^{\circ}\text{C}$  for 75 s, and the final extension was done at  $72^{\circ}\text{C}$  for 5 min. Upon confirmation on a 1% agarose gel for the presence of the expected amplicon size (1.3 kb), the PCR product was digested with DpnI in order to remove cell-derived plasmid template from the PCR sample. The reaction mix (230  $\mu\text{L}$ ) contained 195  $\mu\text{L}$  PCR product, 23  $\mu\text{L}$  2 $\times$  reaction buffer and three units of FastDigest DpnI (Thermo), incubated at  $37^{\circ}\text{C}$  in a water bath for 1 h. The PCR product was then purified by Monarch PCR & DNA Cleanup Kit (NEB). Electrocompetent *E. coli* JM101/pSIM5/pAT03 were prepared by growing the strain at  $30^{\circ}\text{C}$  to OD<sub>600</sub> 0.6–0.8 in 10 mL LB (chloramphenicol, carbenicillin). Once the OD<sub>600</sub> was reached, the culture was transferred to a  $42^{\circ}\text{C}$  water bath for exactly 15 min to induce the  $\lambda$ -Red recombinase in pSIM5, followed by cooling on ice for 30 min. Subsequently, 9 mL culture was centrifuged at 8,000 $\times g$  for 6 min in 1.7-mL centrifuge tubes at  $4^{\circ}\text{C}$ . The pellet was washed twice with 4 mL ice-cold 10% glycerol and pellets from two centrifuge tubes were combined in 400  $\mu\text{L}$  ice-cold 10% glycerol. The pooled pellets were resuspended in 100  $\mu\text{L}$  10% glycerol and stored at  $-80^{\circ}\text{C}$ . The electrocompetent cells were transformed with 500 ng linearized PCR product using a BioRad Pulse Controller at 2.5 kV, 25  $\mu\text{F}$ , and 200  $\Omega$ . Following incubation at  $30^{\circ}\text{C}$  for 2.5 h, 100  $\mu\text{L}$  culture was plated onto LB (tetracycline) and incubated at  $30^{\circ}\text{C}$  for up to 48 h. Tetracycline-resistant colonies were screened for successful exchange of the ampicillin resistance gene with the tetracycline resistance gene by PCR using primers CHCK5Tet and CHCK3Tet ([S3 Text](#)). The colonies were grown overnight in 2.5 mL LB (tetracycline) and 1  $\mu\text{L}$  culture was added to the PCR mix (25  $\mu\text{L}$ ; 1 $\times$  Taq Frogga mix (Frogga Bio), with primers at 0.2  $\mu\text{M}$ ) and the amplification was done as follows: initial denaturation at  $98^{\circ}\text{C}$  for 3 min followed by 25 cycles of  $96^{\circ}\text{C}$  for 10 s,  $52^{\circ}\text{C}$  for 30 s,  $72^{\circ}\text{C}$  for 1 min and the final extension was done at  $72^{\circ}\text{C}$  for 5 min. pSIM5 was cured from the strain by two cycles of growth at  $42^{\circ}\text{C}$ . pAT03a was isolated using the Monarch Plasmid Miniprep Kit (NEB) and sequenced to confirm the fidelity of the tetracycline resistance gene.

**Construction of *A. baumannii* HUMC1::gtr6-hygromycin.** First, electrocompetent HUMC1 was prepared as follows. Colonies from an overnight LB agar plate were mechanically

harvested and resuspended in 1 mL of LB, 500  $\mu$ L of which was inoculated into 250 mL LB broth and incubated at 37°C while shaking at 275 rpm. The culture was harvested at an OD<sub>600</sub> of 0.40–0.45, distributed into two 250 mL bottles and pelleted at 8000 x g for 8 mins at 4°C. The pellets were resuspended in equal volumes of ice cold 10% glycerol, followed by another wash with 70 mL of 10% glycerol. Then the two pellets were combined, washed with 50 mL of 10% glycerol and resuspended in a final volume of 500  $\mu$ L of 10% glycerol. The plasmid pAT04 (500 ng) (S2B Fig), which possesses the *A. baumannii* recombination (Rec<sub>Ab</sub>) system (S1 Text), was transformed into 100  $\mu$ L of HUMC1 competent cells via electroporation (Biorad pulse controller at 1.8 kV, 25  $\mu$ F, 200  $\Omega$ ). Transformed clones, (selected on LB tetracycline), were confirmed for presence of pAT04 by colony-PCR using the primers CHCK5Tet and CHCK3Tet as described above and verified as HUMC1/pAT04.

Next, the hygromycin resistance gene cassette with FRT sites was synthesized by Integrated DNA Technologies. The cassette was delivered in a pUC57 background (S2C Fig). Since the *gtr6* neighborhood of *A. baumannii* strain 15827 has the identical sequence as that in HUMC1 and possess wild-type *gtr6*, purified Ab15827 DNA was used as template for amplification of *gtr6*, starting from the 5' end of the ORF up to 100 bases flanking the 3' end.

Then, a plasmid construct (S2D Fig) was designed and generated by Gibson cloning in which the *gtr6* gene was followed by the hygromycin-FRT cassette and housed in a pUC19 background. *gtr6*, hygromycin-FRT resistance cassette and the pUC19 plasmid were amplified by PCR separately (S1 Text). *gtr6* and the pUC19 were amplified using Q5 High-Fidelity Master Mix (NEB), as described previously. The PCR conditions for *gtr6* were: initial denaturation at 98°C for 3 mins., followed by 35 cycles of 96°C for 10 secs, 60°C for 30 secs, 72°C for 2 mins and 15 secs and the final extension was done at 72°C for 5 mins and for pUC19 were: initial denaturation at 98°C for 3 mins followed by 35 cycles of 96°C for 10 secs, 58°C for 30 secs, 72°C for 2 mins and 15 secs and the final extension was done at 72°C for 5 mins. The hygromycin-FRT cassette was amplified using Phusion HotStart II DNA Polymerase (Thermo Scientific). The reaction mixture (200  $\mu$ L) contained 80 ng of template (pSC2), 1X GC buffer, 0.5  $\mu$ M of each primer, 0.2 mM of each dNTPs and 3% DMSO. The PCR conditions for hygromycin-FRT gene cassette were: initial denaturation at 98°C for 3 mins followed by 35 cycles of 96°C for 10 secs, 70°C for 30 secs, 72°C for 2 mins and the final extension was done at 72°C for 5 mins. The three linear PCR amplicons were then purified using Monarch PCR & DNA Cleanup Kit (NEB). Equimolar amounts of these purified linearized fragments were ligated and circularized using Gibson Assembly Cloning Kit (NEB) following manufacturer's protocol with the resultant generation of pSC1. 10  $\mu$ L of the Gibson mix was transformed into electrocompetent *E. coli* JM101 as described previously. Recombinant clones (JM101/pSC1) were selected by resistance to hygromycin and ampicillin.

Next, the plasmid pSC1 (S2D Fig) was isolated from JM101/pSC1 to enable amplification of the chimeric *gtr6*-hygromycin-FRT cassette using the primers Gtr6-Hyg 5 and Gtr6-Hyg 3 (S3 Text) and Phusion HotStart II DNA Polymerase as described previously. The PCR conditions were: initial denaturation at 98°C for 3 mins followed by 35 cycles of 96°C for 10 secs, 68°C for 30 secs, 72°C for 2 mins and 15 secs and the final extension was done at 72°C for 5 mins. The amplified product was concentrated to 1  $\mu$ g/ $\mu$ L. Five  $\mu$ g of the linear chimeric *gtr6*-hygromycin-FRT cassette was transformed into electrocompetent *A. baumannii* HUMC1/pAT04. Electrocompetent *A. baumannii* HUMC1/pAT04 was prepared as described above with the following modifications: after 45 mins of growth, 2mM IPTG (which induces the recombinase) was added to the culture used to generate electrocompetent cells; IPTG (2mM) was also added to 4 mL of LB during the revival of the transformed culture, post-electroporation. Recombinant clones were selected on LB hygromycin (500  $\mu$ g/mL). The correct site of recombination for the chimeric *gtr6*-hygromycin-FRT cassette into the chromosome, was

confirmed by PCR amplification of the flanking regions of the *gtr6* neighborhood (Gtr6-Hyg Internal 5 and Gtr6-Hyg Flanking 3). The loss of the transposes (as expected) was also confirmed by sequencing the recombinant *gtr6* gene. The pAT04 was cured by selecting the HUMC1::*gtr6*-hygromycin strain consecutively on LB hygromycin for three times. Loss of PCR amplification by CHK5Tet and CHK3Tet primers confirmed loss of pAT04.

**Flippase mediated excision of hygromycin resistance cassette HUMC1::*gtr6*-hygromycin to create HUMC1::*gtr6*.** Electrocompetent cells of pAT04-cured HUMC1::*gtr6*-hygromycin were prepared as described above. The flippase encoding plasmid pAT03a (560ng) was transformed into HUMC1::*gtr6*-hygromycin via electroporation (100 $\mu$ L competent cells in a 0.2cm cuvette at 1.8 kV, 25  $\mu$ F and 200  $\Omega$ ). The cells were subsequently grown in 1mL of LB broth containing 2mM IPTG (to induce flippase expression) for 90 min. at 37°C, 275 rpm. Cell suspensions were plated on LB plates containing tetracycline at 20  $\mu$ g/mL. Recombinant colonies of interest in which flippase-mediated excision of the hygromycin cassette occurred were identified as tetracycline resistant, hygromycin sensitive when screened on LB tetracycline and LB hygromycin (500  $\mu$ g/ $\mu$ L) plates. Colonies with this phenotype were further screened for the absence of the hygromycin cassette via PCR (2xFrogga Mix, primers Gtr6-Hyg Internal 5 and Gtr6-Hyg Flanking 3 (S3 Text), 95°C– 2min, [95°C– 30sec, 53°C– 30sec, 72°C– 1:30 min] x25, 72°C– 10min, 4°C—hold). Several colonies identified as having lost the hygromycin cassette were grown consecutively 6 times without any selection pressure in order to cure pAT03a. Phenotypic sensitivity to tetracycline followed by subsequent physical confirmation of the loss of the tetracycline gene cassette via PCR (using primers CHK5Tet and CHK3Tet as described) confirmed the loss of pAT03a. One colony of HUMC1::*gtr6* was used for further study. Genomic DNA was extracted and 62 ng was used as template in a 25 $\mu$ L PCR reaction with outside primers 1128/1129 (S3 Text) (0.5nM each), dNTPs (0.2nM), 5% DMSO, GC buffer and Phusion Hotstart II DNA Polymerase (Thermo Scientific). The reaction was visualized on an agarose gel and the band of the expected size was gel purified using the Monarch Gel Extraction Kit (NEB). Sequence analysis confirmed that HUMC1::*gtr6* possessed the restored genotype.

**Construction of the ATCC 17978  $\Delta$ *gtr6*/pSC1a rescue plasmid.** In order to make pSC1, the *gtr6*-*hyg* chimeric cassette was inserted in the middle of the *lacZ* gene of puc19, where all of the gene except of 5' end 32 bases, was deleted. However, the *gtr6* gene in pSC1 was devoid of its promoter and was not inducible. Additionally, as a small portion of the 5' end of the *lacZ* gene remained, the *gtr6* gene could not be induced by the lac promoter either. Hence, we decided to delete the 5' end fragment of *lacZ* from the *gtr6* upstream region and clone the 192 base pair long indigenous promoter region of *gtr6* upstream of the gene itself thus creating pSC1a. The plasmid pSC1 (S2E Fig) and the *gtr6* indigenous promoter sequence (192 bp) were PCR amplified (S3 Text). The linearized plasmid PCR product was purified with NEB PCR clean up kit using manufacturer's protocol while the promoter region PCR product was gel purified by NEB Gel purification kit following manufacturer's protocol. The linear fragments were subjected to Gibson cloning using NEB Gibson Cloning kit following manufacturer's protocol and was transformed in to NEB 5 $\alpha$  Competent *E. coli* cells. The recombinant clones were selected on LB Hygromycin (150 $\mu$ g/mL) agar plates. Putative clones were grown overnight in 5mL LB Hygromycin (150 $\mu$ g/mL) broth and 1 $\mu$ L was used to perform colony PCR with primers Gtr6-Hyg Internal 5&3 as described previously.

## RNA sequencing

RNA sequencing was performed via a commercial platform (Novogene Corporation Inc, Sacramento, CA). Bacterial cells were grown overnight in tryptic soy broth, sub-cultured to



logarithmic phase in tryptic soy broth, and cell pellets snap-frozen in liquid nitrogen. Following RNA extraction, total RNA was quantified, checked for purity via spectrophotometer, checked for integrity, and quantified using the RNA 6000 assay on the Bioanalyzer 2100 system. 1  $\mu\text{g}$  total RNA was used per sample and sequencing libraries were analyzed via an Illumina sequence platform. Following quality control, reads were mapped to the ATCC 17978 reference genome and differential gene expression was quantified using the DESeq2 R package.

### Phagocytosis assays

We utilized RAW 264.7 macrophage-like cells activated for 24 hours with interferon- $\gamma$  (IFN- $\gamma$ ), a condition comparable to activation with LPS [40,41] and previously utilized to successfully phagocytose *A. baumannii* strains [7]. RAW 264.7 cells were passaged in Dulbecco's Modified Eagle Medium (DMEM) (Gibco, Thermo Fisher Scientific, Waltham, MA USA #11875135) supplemented with 10% Fetal Bovine Serum (FBS) (Atlanta Biologicals Inc, Flowery Branch, GA USA #S11150) at 37°C with 5% CO<sub>2</sub> to a minimum of three and no more than 15 passages. After washing and counting, a concentration of  $5 \times 10^5$  cells/mL were stimulated with 1  $\mu\text{g}/\text{mL}$  IFN- $\gamma$  (Peprotech, Rocky Hill, NJ USA #315-05-B) and deposited onto glass coverslips, followed by overnight incubation.

Where indicated, macrophages were incubated prior to the addition of bacteria for 30 min at 37°C and 5% CO<sub>2</sub> with soluble carbohydrates or antibodies. To block uptake, 0.5 mg/mL Mannan (Sigma-Aldrich, St. Louis, MO USA #M7504-100MG), 0.5 mg/mL Laminarin (Sigma-Aldrich #L9634-500MG), 0.1 mg/mL Dextran Sulfate (Sigma-Aldrich #D4911-1G), or 10 mM EDTA (VWR, #82021-254) were added to cells prior to incubation with bacteria. To neutralize receptors, anti-Dectin-1 (Invivogen, San Diego, CA USA #mabg-mdect), anti-CR3 (Thermo-Fisher, #14-0181-82), and anti-MR (Invivogen, #Mab-hMR) antibodies were added at 1:200. Bacterial strains were grown in Tryptic Soy Broth (TSB) (VWR, Radnor, PA USA #90000-372) overnight at 37°C with shaking at 200 rpm, sub-cultured to logarithmic phase, washed three times in PBS, diluted to  $2 \times 10^8$  CFUs/mL based on OD<sub>600</sub> measurements, and added to RAW 264.7 cells at a multiplicity of infection of 20:1 in Hanks' Balanced Salt Solution (HBSS) (VWR, #45001-101) supplemented with 10% complement-active CD-1 mouse serum (Innovative Research Inc., Novi, MI USA). In the case of complement dilution, two-fold dilutions of complement-active mouse serum in PBS were generated and added to the assays, with the total assay volume remaining at 1 mL. When performing mixed capsule assays, 1  $\mu\text{L}$  purified capsule from strains was added to the culture plate prior to adding bacteria. Culture plates were centrifuged at 300 $\times$ g for 5 min and incubated for 1 h at 37°C with 5% CO<sub>2</sub>. Plates were washed three times in HBSS, stained with HEMA-3 stain (Thermo Fisher Scientific, #22-122911), and mounted on glass microscope slides with VectaMount AQ aqueous mounting solution (VWR, #H-5501). Macrophages were visualized at 1,000 $\times$  total magnification under oil immersion on a Leica DMLS brightfield microscope (Leica Microsystems Inc., Buffalo Grove, IL USA). The total numbers of internalized bacteria in each fully visible phagocyte on the microscope field were manually counted.

### Gentamicin protection assays

RAW 264.7 cells were activated and prepared as described above, and co-incubated with ATCC 17978 bacteria at a 20:1 MOI, with and without 200  $\mu\text{g}/\text{mL}$  gentamicin and/or 20  $\mu\text{g}/\text{mL}$  cytochalasin D at 37°C. At the 1-hour timepoint supernatant in gentamicin-free wells was agitated by gentle pipetting to resuspend un-phagocytosed bacteria and 100 $\mu\text{L}$  taken for CFU plating. In gentamicin-containing wells, gentamicin was added at the 1-hour timepoint



followed by incubation at 37°C for 30 minutes. The supernatant was removed, macrophages were washed twice with HBSS, and 0.5% sodium deoxycholate added to selectively lyse macrophages but not bacterial cells. Cells were scraped from the wells using a pipette tip and 100 μL of supernatant were plated for CFU measurement of internalized bacteria.

### Bacterial capsule purification and quantification

Bacterial cells were grown in 10 mL TSB overnight, centrifuged at 4,000×g for 5 min, and resuspended in 200 μL TAE buffer. 400 μL Lysis Buffer (100 mM SDS, 50 mM Tris, 0.128 mM NaCl) was added and solutions mixed by inversion. 600 μL of 25:24:1 phenol:chloroform:isoamyl alcohol solution was added and the solution was vortexed vigorously for 2 min until cloudy white. Samples were heated at 65°C for 15 min on a dry heating block and centrifuged in a benchtop centrifuge at 10,000 rpm for 15 min at 4°C. The upper aqueous phase was transferred to a new 1-mL tube and 200 μL sterile water was added. 50 μL 3 M sodium acetate and 1 mL ice-cold ethanol were added and the solution was mixed slowly by inversion. The solution was then held at -80°C overnight. The capsule extract was then purified by adding 3 μL 10 mg/mL DNase and 3 μL 10 mg/mL RNase and incubated at 37°C for 45 min. 5 μL 20 μg/mL Proteinase K was then added and the solution was incubated at 56°C for 1 h. An equal volume of phenol-chloroform-isoamyl alcohol mix was added and the solution was vigorously vortexed for 30 s. The samples were centrifuged at 10,000 rpm for 15 min at 4°C and the aqueous phase was transferred to a new 1.7-mL tube. 193 μL 50 mM Tris, 7 μL 3 M sodium acetate, a 3-fold greater volume of ice-cold ethanol was added and the samples were placed at -80°C overnight. The samples were spun at 10,000 rpm in a benchtop centrifuge at 4°C for 30 min, and resuspended in 50 μL sterile water.

To quantify total capsule carbohydrate content, bacterial cells were prepared as above and diluted to OD<sub>600</sub> 0.5 and plated to count CFUs. After extraction in parallel as described above, total carbohydrate content was assayed via colorimetry as described elsewhere [42,43] in 96-well plates in a plate reader set to detect absorbance at 315 nm.

### siRNA knockdown in RAW 264.7 cells

RAW 264.7 cells were passaged in RPMI Medium 1640 (Gibco, Thermo Fisher Scientific, Waltham, MA USA #11875135) supplemented with 10% FBS at 37°C with 5% CO<sub>2</sub>. 2.5×10<sup>5</sup> cells were deposited onto glass coverslips in 6-well tissue-culture treated plates, centrifuged at 300×g for 5 min, and allowed to adhere via incubation at 37°C with 5% CO<sub>2</sub> for 1 h. Lipofectamine RNAiMAX Reagent (Thermo Fisher Scientific, Waltham, MA US #13387) was diluted in Opti-MEM Reduced Serum Medium (Thermo Fisher Scientific #31985062), and mixed 1:1 with anti-Dectin-1, anti-CR3, or scramble Mouse Silencer Select siRNA (Thermo Fisher Scientific #430817) diluted in Opti-MEM Reduced Serum Medium per manufacturer recommendations. siRNA-lipid complexes were added to wells with RAW 264.7 cells at 12.5 pmol and incubated for 24 h at 37°C with 5% CO<sub>2</sub>. Cells were then activated with 1 μg/mL IFN-γ, incubated for a further 24 h, and macrophage uptake assays were performed as above. To verify siRNA knockdown efficiency, CR3 or scramble siRNA knockdown was performed as described above, total RNA extracted, converted to cDNA, and finally measured via ΔΔCt RT-qPCR and expressed as a percentage of knockdown efficiency compared to the housekeeping gene GAPDH.

### Harvesting of elicited peritoneal phagocytes

3.8% Brewer Thioglycollate Broth was prepared by suspending 38 g Brewer Thioglycollate Medium (Sigma-Aldrich #B2551) in 1 L distilled water and sterilized by autoclaving at 121°C

for 15 min. Male wild-type C57BL/6 mice, Dectin-1 KO, and CR3-KO mice (The Jackson Laboratory, Bar Harbor, ME) were injected intraperitoneally with 2 mL thioglycolate broth and peritoneal fluid was harvested: 72 h post-injection for macrophages; 24 h post-injection for neutrophils [44,45]. For harvesting, 5 mL warm PBS was injected directly into the peritoneum after euthanasia and aspirated. Suspended cells were then washed and resuspended in DMEM supplemented with 10% FBS. Cells were then incubated in T75 tissue-culture flasks for 2 h at 37°C with 5% CO<sub>2</sub> to allow for adhesion. Non-adherent cells were removed by washing twice with warm DPBS, and adherent cells were resuspended in DMEM with 10% FBS followed by phagocytosis assays as described above.

### ***In Vivo* infection model**

Bacterial cultures were grown to logarithmic phase and washed as described previously[7]. Cultures were diluted so that 250 μL contained the target inoculum, which varied by strain and experiment. For lethal concentration and CFU experiments, male C3HeB/Fe mice aged 8–12 weeks were purchased from The Jackson Laboratory. For all knockout mouse experiments, male mice aged 8–12 weeks on a C57BL/6 background (strain # 003991 for CR3 KO and # 012337 for Dectin-1) along with wild-type controls were purchased from The Jackson Laboratory. Mice were briefly warmed under a heat lamp to dilate tail veins and 250 μL bacterial inocula were injected into the lateral tail vein. Mice were either monitored for survival with a moribundity endpoint in accordance with IACUC protocol or were euthanized following the administration of ketamine/xylazine and heparin per manufacturer instructions. Blood was collected from euthanized animals via cardiac puncture and serial dilutions plated on TSA for enumeration of CFUs. For cobra venom factor (CVF), 15 μg recombinant CVF resuspended in 200 μL PBS was injected intraperitoneally 48 hours prior to infection.

### **Bacterial flow cytometry**

Bacterial cultures were grown to logarithmic phase and washed as described previously.  $1 \times 10^7$  CFU were incubated with 10% complement-active mouse serum for 1 h at 37°C, washed three times with PBS, incubated with antibodies against mouse complement factor C3b (Thermo Fisher, clone 6C9) or an isotype control for 30 min, washed three times with PBS, and incubated with a secondary fluorescent antibody followed by three washes. Samples were then resuspended in FACS buffer and run on a Becton-Dickinson FACS Canto II flow cytometer, collecting 20,000 events per sample and gating on single cells with positive gates established at a fluorescence excluding 99% of the isotype control samples.

### **Statistics**

All *in vitro* experiments were performed with one biological replicate and were repeated once. For phagocytosis assays, five images were taken per coverslip and all cells within each image were counted. Median bacteria per macrophage were measured and non-parametric Mann-Whitney statistical tests were performed. For flow cytometry, all experiments were repeated once and 20,000 events per sample were collected. Fluorescence gates were established by excluding 99% of isotype control events. Statistical significance of proportions by positive and negative fluorescence was established via Chi-square contingency tests. *In vivo* experiments consisted of  $n = 5$  animals per condition and were repeated once. Replicates were pooled and statistical significance was established via log-rank (Mantel-Cox) survival tests. All statistical tests were generated using Prism GraphPad 6 software.

## Supporting information

**S1 Fig. RNA Sequencing of HUMC1, SiRNA knockdown efficiency of CR3 in RAW 264.7 cells and phagocytosis assays with complement-depleted serum.** (A) RNA sequencing of wild-type HUMC1 and HUMC1::*gtr6* showed no differential gene expression. (B) RAW 264.7 cells were incubated with anti-CR3 or scramble siRNA and knockdown efficiency measured via  $\Delta\Delta C_t$  RT-qPCR vs. the GAPDH housekeeping gene. (C) RAW 264.7 cells were incubated with ATCC 17978 in normal serum, in serum-free conditions, in serum selectively depleted of C3, and serum pre-treated with 15 $\mu$ g/mL cobra venom factor to deplete C3 + C5. \* =  $p < 0.01$ . (TIF)

**S2 Fig. Plasmids synthesized for mutant generation.** For the generation of the HUMC1::*gtr6* mutant, plasmids (A) pAT03a-Tet, (B) pAT04, (C) pSC2, (D) pSC1 and (E) pSC1a were all synthesized as described in the Materials and Methods section. (TIF)

**S1 Text. List of all plasmids used in mutant generation.** Plasmid name, drug marker, function, and origin are listed. (DOCX)

**S2 Text. Sequence of hygromycin resistance cassette for mutant generation.** The cassette includes the FRT site (red), promoter site for hygromycin (green), and the hygromycin resistance gene (blue). (DOCX)

**S3 Text. List of all primers used for mutant generation.** Primer name, description, and sequence are listed. Underline—first/last 126bp of the *gtr6* ORF at the 5' end. (DOCX)

## Author Contributions

**Conceptualization:** Yuli Talyansky, Travis B. Nielsen, Jun Yan, Gisela Di Venanzio, Somnath Chakravorty, Amber Ulhaq, Mario F. Feldman, Thomas A. Russo, Evgeny Vinogradov, Brian Luna, Meredith S. Wright, Mark D. Adams, Brad Spellberg.

**Data curation:** Yuli Talyansky, Travis B. Nielsen, Jun Yan, Ulrike Carlino-Macdonald, Gisela Di Venanzio, Somnath Chakravorty, Amber Ulhaq, Mario F. Feldman, Thomas A. Russo, Evgeny Vinogradov, Brian Luna, Meredith S. Wright, Mark D. Adams, Brad Spellberg.

**Formal analysis:** Yuli Talyansky, Travis B. Nielsen, Jun Yan, Ulrike Carlino-Macdonald, Gisela Di Venanzio, Somnath Chakravorty, Amber Ulhaq, Mario F. Feldman, Thomas A. Russo, Evgeny Vinogradov, Brian Luna, Meredith S. Wright, Mark D. Adams, Brad Spellberg.

**Funding acquisition:** Mario F. Feldman, Thomas A. Russo, Brian Luna, Brad Spellberg.

**Investigation:** Yuli Talyansky, Travis B. Nielsen, Jun Yan, Ulrike Carlino-Macdonald, Gisela Di Venanzio, Somnath Chakravorty, Mario F. Feldman, Thomas A. Russo, Evgeny Vinogradov, Brian Luna, Meredith S. Wright, Mark D. Adams, Brad Spellberg.

**Methodology:** Yuli Talyansky, Travis B. Nielsen, Jun Yan, Ulrike Carlino-Macdonald, Gisela Di Venanzio, Somnath Chakravorty, Amber Ulhaq, Mario F. Feldman, Thomas A. Russo, Evgeny Vinogradov, Brian Luna, Meredith S. Wright, Mark D. Adams, Brad Spellberg.

**Project administration:** Mario F. Feldman, Thomas A. Russo, Brian Luna, Brad Spellberg.

**Resources:** Mario F. Feldman, Thomas A. Russo, Evgeny Vinogradov, Brian Luna, Brad Spellberg.

**Software:** Yuli Talyansky, Travis B. Nielsen, Jun Yan, Amber Ulhaq, Mario F. Feldman, Thomas A. Russo, Evgeny Vinogradov, Brian Luna, Meredith S. Wright, Mark D. Adams, Brad Spellberg.

**Supervision:** Mario F. Feldman, Thomas A. Russo, Brian Luna, Brad Spellberg.

**Validation:** Yuli Talyansky, Travis B. Nielsen, Jun Yan, Ulrike Carlino-Macdonald, Gisela Di Venanzio, Somnath Chakravorty, Amber Ulhaq, Mario F. Feldman, Thomas A. Russo, Evgeny Vinogradov, Brian Luna, Brad Spellberg.

**Visualization:** Yuli Talyansky, Travis B. Nielsen, Jun Yan, Ulrike Carlino-Macdonald, Evgeny Vinogradov, Brian Luna, Brad Spellberg.

**Writing – original draft:** Yuli Talyansky.

**Writing – review & editing:** Yuli Talyansky, Travis B. Nielsen, Jun Yan, Ulrike Carlino-Macdonald, Gisela Di Venanzio, Somnath Chakravorty, Amber Ulhaq, Mario F. Feldman, Thomas A. Russo, Evgeny Vinogradov, Brian Luna, Meredith S. Wright, Mark D. Adams, Brad Spellberg.

## References

1. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *The Lancet Infectious Diseases*. 2018; 18(3):318–27. [https://doi.org/10.1016/S1473-3099\(17\)30753-3](https://doi.org/10.1016/S1473-3099(17)30753-3) PMID: 29276051
2. Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B. Clinical and Pathophysiological Overview of *Acinetobacter* Infections: a Century of Challenges. *Clin Microbiol Rev*. 2017; 30(1):409–47. <https://doi.org/10.1128/CMR.00058-16> PMID: 27974412
3. Peleg AY, Seifert H, Paterson DL. *Acinetobacter baumannii*: Emergence of a Successful Pathogen. *Clinical Microbiology Reviews*. 2008; 21(3):538–82. <https://doi.org/10.1128/CMR.00058-07> PMID: 18625687
4. Li F-J, Starrs L, Burgio G. Tug of war between *Acinetobacter baumannii* and host immune responses. *Pathogens and Disease*. 2019; 76(9).
5. Nichols L. Death from pan-resistant superbug. *Autopsy & case reports*. 2019; 9(3). <https://doi.org/10.4322/acr.2019.106> PMID: 31440482
6. Lee C-R, Lee JH, Park M, Park KS, Bae IK, Kim YB, et al. Biology of *Acinetobacter baumannii*: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. *Frontiers in cellular and infection microbiology*. 2017; 7:55. <https://doi.org/10.3389/fcimb.2017.00055> PMID: 28348979
7. Nielsen TB, Pantapalangkoor P, Luna BM, Bruhn KW, Yan J, Dekitani K, et al. Monoclonal antibody protects against *Acinetobacter baumannii* infection by enhancing bacterial clearance and evading sepsis. *The Journal of infectious diseases*. 2017; 216(4):489–501. <https://doi.org/10.1093/infdis/jix315> PMID: 28931235
8. Lin L, Tan B, Pantapalangkoor P, Ho T, Baquir B, Tomaras A, et al. Inhibition of LpxC protects mice from resistant *Acinetobacter baumannii* by modulating inflammation and enhancing phagocytosis. *MBio*. 2012; 3(5):e00312–12. <https://doi.org/10.1128/mBio.00312-12> PMID: 23033474
9. Weber BS, Harding CM, Feldman MF. Pathogenic *Acinetobacter*: from the cell surface to infinity and beyond. *Journal of bacteriology*. 2016; 198(6):880–7.
10. Russo TA, Luke NR, Beanan JM, Olson R, Sauberan SL, MacDonald U, et al. The K1 capsular polysaccharide of *Acinetobacter baumannii* strain 307–0294 is a major virulence factor. *Infection and immunity*. 2010; 78(9):3993–4000. <https://doi.org/10.1128/IAI.00366-10> PMID: 20643860
11. Geisinger E, Isberg RR. Antibiotic modulation of capsular exopolysaccharide and virulence in *Acinetobacter baumannii*. *PLoS Pathog*. 2015; 11(2):e1004691. <https://doi.org/10.1371/journal.ppat.1004691> PMID: 25679516

12. Bruhn KW, Pantapalangkoor P, Nielsen T, Tan B, Junus J, Hujer KM, et al. Host fate is rapidly determined by innate effector-microbial interactions during *Acinetobacter baumannii* bacteremia. *J Infect Dis*. 2015; 211(8):1296–305. <https://doi.org/10.1093/infdis/jiu593> PMID: 25378635
13. Kenyon JJ, Hall RM. Variation in the complex carbohydrate biosynthesis loci of *Acinetobacter baumannii* genomes. *PLoS One*. 2013; 8(4):e62160. <https://doi.org/10.1371/journal.pone.0062160> PMID: 23614028
14. Luna BM, Yan J, Reyna Z, Moon E, Nielsen TB, Reza H, et al. Natural history of *Acinetobacter baumannii* infection in mice. *PloS one*. 2019; 14(7). <https://doi.org/10.1371/journal.pone.0219824> PMID: 31318907
15. Huang H, Ostroff GR, Lee CK, Agarwal S, Ram S, Rice PA, et al. Relative contributions of dectin-1 and complement to immune responses to particulate  $\beta$ -glucans. *Journal of immunology (Baltimore, Md: 1950)*. 2012; 189(1):312–7. <https://doi.org/10.4049/jimmunol.1200603> PMID: 22649195
16. Carralot J-P, Kim T-K, Lenseigne B, Boese AS, Sommer P, Genovesio A, et al. Automated High-Throughput siRNA Transfection in Raw 264.7 Macrophages: A Case Study for Optimization Procedure. *Journal of Biomolecular Screening*. 2009; 14(2):151–60. <https://doi.org/10.1177/1087057108328762> PMID: 19196705
17. Xia Y, Větvicka V, Yan J, Hanikýřová M, Mayadas T, Ross GD. The  $\beta$ -glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. *The Journal of Immunology*. 1999; 162(4):2281–90. PMID: 9973505
18. Thornton BP, Větvicka V, Pitman M, Goldman RC, Ross GD. Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). *The Journal of Immunology*. 1996; 156(3):1235–46. PMID: 8558003
19. Vogel C-W, Fritzing DC. Cobra Venom Factor: The Unique Component of Cobra Venom That Activates the Complement System. In: Inagaki H, Vogel C-W, Mukherjee AK, Rahmy TR, editors. *Snake Venoms*. Dordrecht: Springer Netherlands; 2017. p. 345–404.
20. Falkow S. Molecular Koch's postulates applied to microbial pathogenicity. *Rev Infect Dis*. 1988; 10 Suppl 2:S274–6. [https://doi.org/10.1093/cid/10.supplement\\_2.s274](https://doi.org/10.1093/cid/10.supplement_2.s274) PMID: 3055197
21. Kenyon JJ, Holt KE, Pickard D, Dougan G, Hall RM. Insertions in the OCL1 locus of *Acinetobacter baumannii* lead to shortened lipooligosaccharides. *Research in Microbiology*. 2014; 165(6):472–5. <https://doi.org/10.1016/j.resmic.2014.05.034> PMID: 24861001
22. Adams MD, Wright MS, Karichu JK, Venepally P, Fouts DE, Chan AP, et al. Rapid replacement of *Acinetobacter baumannii* strains accompanied by changes in lipooligosaccharide loci and resistance gene repertoire. *MBio*. 2019; 10(2):e00356–19. <https://doi.org/10.1128/mBio.00356-19> PMID: 30914511
23. Vallenet D, Nordmann P, Barbe V, Poirel L, Mangenot S, Bataille E, et al. Comparative analysis of *Acinetobacter*: three genomes for three lifestyles. *PloS one [Internet]*. 2008 2008; 3(3):[e1805 p.]. <https://doi.org/10.1371/journal.pone.0001805> PMID: 18350144
24. Ross G, Cain J, Lachmann P. Membrane complement receptor type three (CR3) has lectin-like properties analogous to bovine conglutinin as functions as a receptor for zymosan and rabbit erythrocytes as well as a receptor for iC3b. *The Journal of Immunology*. 1985; 134(5):3307–15. PMID: 2984286
25. Ross GD. Regulation of the Adhesion versus Cytotoxic Functions of the Mac-1/CR3/ $\alpha$  M  $\beta$  2-Integrin Glycoprotein. *Critical Reviews™ in Immunology*. 2000; 20(3).
26. Chonn A, Cullis P, Devine D. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. *The Journal of immunology*. 1991; 146(12):4234–41. PMID: 2040798
27. Edwards M, Kasper D, Jennings H, Baker C, Nicholson-Weller A. Capsular sialic acid prevents activation of the alternative complement pathway by type III, group B streptococci. *The Journal of Immunology*. 1982; 128(3):1278–83. PMID: 7035562
28. Arbatsky NP, Shneider MM, Kenyon JJ, Shashkov AS, Popova AV, Miroshnikov KA, et al. Structure of the neutral capsular polysaccharide of *Acinetobacter baumannii* NIPH146 that carries the KL37 capsule gene cluster. *Carbohydrate Research*. 2015; 413:12–5. <https://doi.org/10.1016/j.carres.2015.05.003> PMID: 26057991
29. Singh JK, Adams FG, Brown MH. Diversity and Function of Capsular Polysaccharide in *Acinetobacter baumannii*. *Frontiers in Microbiology*. 2019; 9(3301). <https://doi.org/10.3389/fmicb.2018.03301> PMID: 30687280
30. Vinogradov E, MacLean L, Xu HH, Chen W. The structure of the polysaccharide isolated from *Acinetobacter baumannii* strain LAC-4. *Carbohydrate research*. 2014; 390:42–5. <https://doi.org/10.1016/j.carres.2014.03.001> PMID: 24690675



31. Ou H-Y, Kuang SN, He X, Molgora BM, Ewing PJ, Deng Z, et al. Complete genome sequence of hyper-virulent and outbreak-associated *Acinetobacter baumannii* strain LAC-4: epidemiology, resistance genetic determinants and potential virulence factors. *Scientific reports*. 2015; 5:8643–. <https://doi.org/10.1038/srep08643> PMID: 25728466
32. van Bruggen R, Drewniak A, Jansen M, van Houdt M, Roos D, Chapel H, et al. Complement receptor 3, not Dectin-1, is the major receptor on human neutrophils for beta-glucan-bearing particles. *Mol Immunol*. 2009; 47(2–3):575–81. <https://doi.org/10.1016/j.molimm.2009.09.018> PMID: 19811837
33. Li X, Utomo A, Cullere X, Choi MM, Milner DA Jr, Venkatesh D, et al. The  $\beta$ -glucan receptor Dectin-1 activates the integrin Mac-1 in neutrophils via Vav protein signaling to promote *Candida albicans* clearance. *Cell host & microbe*. 2011; 10(6):603–15. <https://doi.org/10.1016/j.chom.2011.10.009> PMID: 22177564
34. Jin JS, Kwon S-O, Moon DC, Gurung M, Lee JH, Kim SI, et al. *Acinetobacter baumannii* secretes cytotoxic outer membrane protein A via outer membrane vesicles. *PLoS one*. 2011; 6(2):e17027. <https://doi.org/10.1371/journal.pone.0017027> PMID: 21386968
35. Harding CM, Hennon SW, Feldman MF. Uncovering the mechanisms of *Acinetobacter baumannii* virulence. *Nature Reviews Microbiology*. 2018; 16(2):91. <https://doi.org/10.1038/nrmicro.2017.148> PMID: 29249812
36. Russo TA, MacDonald U, Beanan JM, Olson R, MacDonald IJ, Sauberman SL, et al. Penicillin-binding protein 7/8 contributes to the survival of *Acinetobacter baumannii* in vitro and in vivo. *The Journal of infectious diseases*. 2009; 199(4):513–21. <https://doi.org/10.1086/596317> PMID: 19143563
37. Tucker AT, Nowicki EM, Boll JM, Knauf GA, Burdis NC, Trent MS, et al. Defining gene-phenotype relationships in *Acinetobacter baumannii* through one-step chromosomal gene inactivation. *MBio*. 2014; 5(4):e01313–14. <https://doi.org/10.1128/mBio.01313-14> PMID: 25096877
38. Domenico P, Landolfi DR, Cunha BA. Reduction of capsular polysaccharide and potentiation of aminoglycoside inhibition in Gram-negative bacteria by bismuth subsalicylate. *Journal of Antimicrobial Chemotherapy*. 1991; 28(6):801–10.
39. Datta S, Costantino N, Court DL. A set of recombinering plasmids for gram-negative bacteria. *Gene*. 2006; 379:109–15. <https://doi.org/10.1016/j.gene.2006.04.018> PMID: 16750601
40. Farber JM. A collection of mRNA species that are inducible in the RAW 264.7 mouse macrophage cell line by gamma interferon and other agents. *Molecular and Cellular Biology*. 1992; 12(4):1535–45. <https://doi.org/10.1128/mcb.12.4.1535> PMID: 1372386
41. Held TK, Weihua X, Yuan L, Kalvakolanu DV, Cross AS. Gamma interferon augments macrophage activation by lipopolysaccharide by two distinct mechanisms, at the signal transduction level and via an autocrine mechanism involving tumor necrosis factor alpha and interleukin-1. *Infection and immunity*. 1999; 67(1):206–12. <https://doi.org/10.1128/IAI.67.1.206-212.1999> PMID: 9864217
42. Brimacombe CA, Beatty JT. Surface polysaccharide extraction and quantification. *Bio Protocol*. 2013; 3:e934.
43. Albalasmeh AA, Berhe AA, Ghezzehei TA. A new method for rapid determination of carbohydrate and total carbon concentrations using UV spectrophotometry. *Carbohydrate polymers*. 2013; 97(2):253–61. <https://doi.org/10.1016/j.carbpol.2013.04.072> PMID: 23911443
44. Layoun A, Samba M, Santos MM. Isolation of murine peritoneal macrophages to carry out gene expression analysis upon Toll-like receptors stimulation. *Journal of visualized experiments: JoVE*. 2015(98):e52749–e. <https://doi.org/10.3791/52749> PMID: 25993651
45. Schleicher U, Bogdan C. Generation, Culture and Flow-Cytometric Characterization of Primary Mouse Macrophages. In: Reiner NE, editor. *Macrophages and Dendritic Cells: Methods and Protocols*. Totowa, NJ: Humana Press; 2009. p. 203–24.